Corbus Pharmaceuticals Holdings Inc. (CRBP)’s Financial Results Comparing With Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB)

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) and Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) are two firms in the Biotechnology that compete against each other. Below is a comparison of their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Corbus Pharmaceuticals Holdings Inc. 2.89M 165.30 49.06M -0.87 0.00
Navidea Biopharmaceuticals Inc 1.45M 20.13 19.16M -0.12 0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.


Table 2 provides us the return on equity, net margins and return on assets of both businesses.

Net Margins Return on Equity Return on Assets
Corbus Pharmaceuticals Holdings Inc. -1,697.58% -88.5% -71.2%
Navidea Biopharmaceuticals Inc -1,321.38% -355.9% -119.6%

Risk and Volatility

Corbus Pharmaceuticals Holdings Inc. has a 2.08 beta, while its volatility is 108.00% which is more volatile than Standard and Poor’s 500. In other hand, Navidea Biopharmaceuticals Inc has beta of -0.53 which is 153.00% less volatile than Standard and Poor’s 500.

Analyst Recommendations

Corbus Pharmaceuticals Holdings Inc. and Navidea Biopharmaceuticals Inc Ratings and Recommendations are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Corbus Pharmaceuticals Holdings Inc. 0 0 4 3.00
Navidea Biopharmaceuticals Inc 0 0 0 0.00

Corbus Pharmaceuticals Holdings Inc.’s upside potential is 243.59% at a $26.25 consensus price target.

Insider and Institutional Ownership

Corbus Pharmaceuticals Holdings Inc. and Navidea Biopharmaceuticals Inc has shares owned by institutional investors as follows: 44.3% and 6.6%. Insiders owned 3.7% of Corbus Pharmaceuticals Holdings Inc. shares. On the other hand, insiders owned about 12.4% of Navidea Biopharmaceuticals Inc’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Corbus Pharmaceuticals Holdings Inc. -2.03% -11.29% 25.19% 15.56% -9.87% -4.79%
Navidea Biopharmaceuticals Inc -25.52% -41.38% -14.85% -39.79% -67.26% -59.69%

For the past year Corbus Pharmaceuticals Holdings Inc.’s stock price has smaller decline than Navidea Biopharmaceuticals Inc.


On 7 of the 11 factors Corbus Pharmaceuticals Holdings Inc. beats Navidea Biopharmaceuticals Inc.

Corbus Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases. Its lead product candidate includes JBT-101, a novel oral endocannabinoid-mimetic drug, which is in Phase 2 clinical trials for the treatment of systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis, and systemic lupus erythematosus diseases. The company is based in Norwood, Massachusetts.

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment. It is also developing NAV5001, an Iodine-123 labeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of Parkinsons disease and other movement disorders with potential use as a diagnostic aid in dementia; diagnostic substances, including technetium 99m tilmanocept and other diagnostic applications; and therapeutic development programs, such as therapeutic applications of its Manocept platform, as well as various development programs and therapeutics. Navidea Biopharmaceuticals, Inc. has research and development agreements with University of California, San Diego. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.